LudwigH., Van BelleS., Barrett-LeeP.: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.Eur J Cancer,40: 2293–2306, 2004.
2.
GroopmanJ.E., ItriL.M.: Chemotherapy-induced anemia in adults: incidence and treatment.J Natl Cancer Inst,91: 1616–1634, 1999.
3.
RizzoJ.D., LichtinA.E., WoolfS.H.: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.J Clin Oncol,20: 1–25, 2002.
4.
Leyland-JonesB.: Breast cancer trial with erythropoietin terminated unexpectedly.Lancet Oncol,4: 459–460, 2003.
5.
HenkeM., LaszigR., RubeC., SchaferU.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial.Lancet,362: 1255–1260, 2003.
6.
FDA Briefing Document, May 4, 2004, Oncologic Drugs Advisory Committee. Safety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy. www.fda.gov/ohrms/dockets/ac/04/briefing/403782_04_FDA-Aranesp-Procrit.htm.
7.
MillerC.B., JonesR.J., PiantadosiS.: Decreased erythropoietin response in patients with the anemia of cancer.N Engl J Med,322: 1690–1692, 1990.
8.
CellaD., LaiS.S., ChangC.H.: Fatigue in cancer patients compared with fatigue in the general United States population.Cancer,94: 528–538, 2002.
9.
CellaD., ZagariM.J., VandorosC.: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referred to the general population.J Clin Oncol,21: 366–373, 2003.
10.
CrawfordJ., WoodD.P., PetrylakD.P.: Relationship between changes in haemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.Cancer,95: 888–895, 2002.
11.
GlaspyJ., BukowskiR., SteinbergD.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice.J Clin Oncol,15: 1218–1234, 1997.
12.
DemetriG.D., KrisM., WadeJ.: Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study.J Clin Oncol,16: 3412–3425, 1998.
13.
GabriloveJ.L., CleelandC.S., LivingstonR.B.: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.J Clin Oncol,19: 2875–2882, 2001.
14.
BottomleyA., ThomasR., Van SteenK.: Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?Lancet Oncol,3: 145–153, 2002.
15.
LittlewoodJ., BajettaE., NortierJ.W.: Effects of epoetin alfa on haematological parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.J Clin Oncol,19: 2865–2874, 2001.
16.
ThewsO., KoenigR., KelleherD.K.: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy induced anemia.Br J Cancer,78: 752–756, 1998.
17.
SilverD.F.: Effects of recombinant human erythropoietin on the antitumour effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect.Gynecol Oncol,73: 280–284, 1999.
18.
GlaserM., MillesiW., KornekG.V.: Impact of haemoglobin level and use of recombinant human erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx.Int J Radiat Oncol Biol Phys,50: 705–715, 2001.
19.
GroganM., ThomasG.M., MelamedI.: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix.Cancer,86: 1528–1536, 1999.
20.
BohliusJ., LangensiepenS., SchwarzerG.: Erythropoietin for patients with malignant disease.Cochrane Database Systematic Review2004; 3: CD003407.
21.
HsiaW.C.: Respiratory function of haemoglobin (review article).N Engl J Med,338: 239–247, 1998.
22.
BokemeyerC., AaproM.S., CourdiA.: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.Eur J Cancer,40: 2201–2216, 2004.
